As the Trump administration works to implement a “most-favored nation” policy, Lilly said it’s “rebalancing” drug prices to ...

Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

AstraZeneca ’s AZN second-quarter 2025 core earnings of $1.09 per American depositary share (ADS) came in line with the Zacks ...

The drug was co-developed with Daiichi Sankyo, showcasing AstraZeneca PLC (NASDAQ:AZN)’s focus on collaborative innovation.

Datroway is the first and only TROP2-directed antibody-drug conjugate (ADC) approved in the U.S. for lung cancer. The drug is jointly developed and commercialized by AstraZeneca and Daiichi Sankyo.

AZ, Daiichi's Datroway scores its 2nd FDA approval—this time in lung cancer subset AstraZeneca and Daiichi Sankyo’s TROP2-targeted antibody-drug conjugate Datroway has picked up its second FDA ...

Cambridge: AstraZeneca and Daiichi Sankyo have announced that Datroway (datopotamab deruxtecan or Dato-DXd) has received accelerated approval from the Food and Drug Administration (FDA) for the ...

Following this approval, AstraZeneca will pay Daiichi Sankyo a $45 million milestone payment for the indication, as outlined in the companies’ collaboration agreement from July 2020. Sales of Datroway ...